MBRX
$2.09
Moleculin Biotech CS
$.11
5.56%
MBRX
Earnings Whisper ®
N/A
2nd Quarter June 2018
Consensus:  ($0.14)
Revenue:  N/A
Tuesday
Aug 14
8:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MBRX reports earnings?
Beat
Meet
Miss

Where is MBRX's stock price going from here?
Up
Flat
Down
Stock chart of MBRX
Analysts
Summary of analysts' recommendations for MBRX
Score
Grade
Pivots
Resistance
$2.30
$2.20
$2.15

$2.05

Support
$2.00
$1.90
$1.85
Tweet
Growth
Description
Metabasis Therapeutics, Inc. discovers and develops drugs for the treatment of liver diseases and metabolic diseases linked to pathways in the liver. They have established a broad pipeline of internally discovered product candidates using their proprietary technologies, NuMimetic and HepDirect.